Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.39
- Piotroski Score 3.00
- Grade Outperform
- Symbol (LIAN)
- Company LianBio
- Price $0.32
- Changes Percentage (-8.28%)
- Change -$0.03
- Day Low $0.28
- Day High $0.35
- Year High $4.99
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
- Last Earnings 02/13/2024
- Ex-Dividend for 5/16 Dividend 03/15/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.82
- Trailing P/E Ratio -0.39
- Forward P/E Ratio -0.39
- P/E Growth -0.39
- Net Income $-110,290,000
Income Statement
Quarterly
Annual
Latest News of LIAN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Xi's Balancing Act on Ukraine Disrupted by Putin-Kim Alliance
China is facing pressure to control its diplomatic allies, Russia and North Korea, amid concerns over escalating tensions. This poses a challenge for President Xi Jinping's efforts to maintain stabili...
By Yahoo! Finance | 16 hours ago -
Rudy Giuliani cleared out his apartment weeks before court deadline to turn over assets, lawyers say
Rudy Giuliani moved valuables out of his Manhattan apartment before a court deadline to surrender assets in a defamation case. Lawyers for the plaintiffs accused him of not disclosing the location of ...
By AP NEWS | 22 hours ago -
Western Alliance Bank review (2024): A business bank that also offers one of the best personal HYSA rates today
Western Alliance Bank, a subsidiary of Western Alliance Bancorporation in Phoenix, provides small business, commercial, and personal banking services. It offers various accounts with fees depending on...
By Yahoo! Finance | 1 day ago
